Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Phase 3CompletedNCT00191009

Eli Lilly and Company124 enrolled

Overview

This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

124

Conditions

Alzheimer Disease

Interventions

atomoxetine hydrochlorideDRUG

placeboDRUG

Eligibility

Sex: ALLMin age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient presents with Alzheimer's Disease based on clinical history. * Patient must have a Mini Mental Status Score between 10 and 26. * Patient must have a reliable caregiver in frequent or daily contact with the patient. * Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months. Exclusion Criteria: * Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease. * Patients who have a history in the past 5 years or any current evidence of major psychiatric illness. * Patients who have narrow angle glaucoma. * Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.

Locations (3)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Sherman Oaks, California, United States

Rochester, New York, United States

Wichita Falls, Texas, United States

Outcomes

Primary Outcomes

To see if Alzheimer's patients receiving a stable dose of an Alzheimer's drug randomly assigned to atomoxetine for approximately 6 months will have cognitive performance improved as measured by the Alzheimer's Disease Assessment Scale - Cognitive

Secondary Outcomes

To see if patients taking an Alzheimer's medication plus atomoxetine for approximately 6 months will be superior to an Alzheimer's medication alone as assessed by the Clinician's Interview-Based Impression of Change (CIBIC+) score.

To see if patients taking an Alzheimer's medication plus atomoxetine will display less comorbid psychological symptoms, such as depression, as assessed by the Neuropsychiatric Inventory (NPI). Patients will receive the NPI once before randomization

To see if current Alzheimer's medications plus atomoxetine compared to Alzheimer's medications plus placebo is better at preserving or slowing cognitive decline as measured by the Alzheimer's Disease Cooperative Study Inventory - Activities of

To show that current Alzheimer's drugs can be taken with atomoxetine without significant side effects.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.